JP2007509184A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509184A5
JP2007509184A5 JP2006537162A JP2006537162A JP2007509184A5 JP 2007509184 A5 JP2007509184 A5 JP 2007509184A5 JP 2006537162 A JP2006537162 A JP 2006537162A JP 2006537162 A JP2006537162 A JP 2006537162A JP 2007509184 A5 JP2007509184 A5 JP 2007509184A5
Authority
JP
Japan
Prior art keywords
phenyl
hydrogen
alkyl
formula
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006537162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509184A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/012081 external-priority patent/WO2005039563A2/en
Publication of JP2007509184A publication Critical patent/JP2007509184A/ja
Publication of JP2007509184A5 publication Critical patent/JP2007509184A5/ja
Pending legal-status Critical Current

Links

JP2006537162A 2003-10-27 2004-10-26 尿失禁の処置におけるニューロキニンアンタゴニストの使用 Pending JP2007509184A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51479103P 2003-10-27 2003-10-27
PCT/EP2004/012081 WO2005039563A2 (en) 2003-10-27 2004-10-26 Use of neurokinin antagonists in the treatment of urinary incontinence

Publications (2)

Publication Number Publication Date
JP2007509184A JP2007509184A (ja) 2007-04-12
JP2007509184A5 true JP2007509184A5 (enExample) 2007-12-06

Family

ID=34520229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006537162A Pending JP2007509184A (ja) 2003-10-27 2004-10-26 尿失禁の処置におけるニューロキニンアンタゴニストの使用

Country Status (9)

Country Link
US (1) US7776851B2 (enExample)
EP (2) EP2158910A1 (enExample)
JP (1) JP2007509184A (enExample)
CN (1) CN1874766A (enExample)
AU (1) AU2004283038B9 (enExample)
BR (1) BRPI0415923A (enExample)
CA (1) CA2543552A1 (enExample)
MX (1) MXPA06004688A (enExample)
WO (1) WO2005039563A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001169A2 (en) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
FR2700472B1 (fr) * 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
US6664253B2 (en) * 2000-10-17 2003-12-16 Boehringer Ingelheim Pharma Kg Neurokinin antagonists
US20040058914A1 (en) * 2000-12-22 2004-03-25 Takayuki Doi Combination drugs
WO2002072145A1 (en) * 2001-03-14 2002-09-19 Ono Pharmaceutical Co., Ltd. Remedies for depression containing ep1 antagonist as the active ingredient
BR0307156A (pt) * 2002-01-18 2004-12-07 Kyorin Seiyaku Kk Derivado de pirimidina bicìclica fundida, composto, antagonistas de receptores e agentes profiláticos e terapêuticos
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
NZ535183A (en) * 2002-03-26 2006-03-31 Kyorin Seiyaku Kk Fused bicyclic pyrimidine derivatives
KR20040099367A (ko) * 2002-03-26 2004-11-26 교린 세이야꾸 가부시키 가이샤 타키키닌 수용체 길항제로서의 축합 바이사이클릭 피리딘 유도체

Similar Documents

Publication Publication Date Title
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EP2210606A3 (en) Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
JP2013541514A5 (enExample)
JP2006182786A5 (enExample)
JP2009504763A5 (enExample)
WO2005044178A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
JP2007519649A5 (enExample)
JP2008538741A (ja) 鬱病の治療用及び/又は予防用の医薬組成物
US7105504B2 (en) Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
JP2009526821A (ja) 注意欠陥多動性障害治療用の新規な医薬組成物
JP2008531714A (ja) 不安障害の治療用及び/又は予防用の医薬組成物
JP2004531517A5 (enExample)
JP2007533722A5 (enExample)
JP2007508360A5 (enExample)
WO2005105088A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
JP2019515884A5 (enExample)
WO2018060463A3 (en) Treatment of prostate cancer
JP2010511631A5 (enExample)
JP2014505107A5 (enExample)
JP2017512211A5 (enExample)
JP2009513713A5 (enExample)
JP2007500160A5 (enExample)
JP2006510659A5 (enExample)
RU2017137008A (ru) Антагонисты толл-подобного рецептора 4 и применение при аутоиммунных заболеваниях печени
JP2007509184A5 (enExample)